Merck Serono Says Partnering Part Of Its Future, Seeks Anti-PD-L1 Deal
This article was originally published in Pharmaceutical Approvals Monthly
Mid-sized German pharma says partnering will be part of its future, as it progresses three key pipeline assets and initiates talks with big pharma players wanting to partner its anti-PD-L1 compound.
You may also be interested in...
By buying U.S.-based Sigma-Aldrich, the German conglomerate hopes to bolster its Millipore lab business, by giving the biopharma technology, tools and service provider added depth and global reach.
Threshold Pharmaceuticals’ lead compound from its hypoxia-activated prodrug platform, TH-302, is partnered with Merck KGaA on one Phase III program and in internal development for another Phase III.
A discussion with internal and external experts restarts clinical development of atacicept for lupus after a two-year hiatus.